Management of Hypercholesterolemia

Patient Assessment and Risk Stratification

The American College of Cardiology recommends initiating moderate to high-intensity statin therapy in patients with a family history of premature CAD and elevated LDL-C levels, such as a 45-year-old male with an LDL of 167 mg/dL and a family history of premature CAD, to achieve at least a 30-50% reduction in LDL-C levels 1, 2
A family history of premature CAD is a significant risk-enhancing factor, and an LDL-C level of 167 mg/dL falls into the range of primary hypercholesterolemia, which is another risk-enhancing factor, according to the 2018 ACC/AHA guidelines 2
South Asian Indians have a unique cardiovascular risk profile characterized by a higher prevalence of atherogenic dyslipidemia (higher triglycerides, lower HDL-C), and Western risk calculators may underestimate cardiovascular risk in this population 3

The American College of Cardiology recommends ruling out secondary causes of hyperlipidemia in patients with elevated LDL-C and family history of premature CAD, and considering measuring Lipoprotein(a) [Lp(a)] levels to further assess cardiovascular risk 1, 2
The goal of statin therapy is to achieve a target LDL-C reduction of ≥30% for moderate-intensity statin or ≥50% for high-intensity statin, and to consider addition of non-statin therapy (ezetimibe) if LDL-C goal not achieved with maximally tolerated statin 1, 2
The American College of Cardiology recommends the following statin therapy:
The following target LDL-C goals are recommended:
Regular monitoring and patient education are essential to improve medication adherence, and LDL-C levels should be assessed 4-12 weeks after initiating statin therapy or dose adjustment, and monitored every 3-12 months thereafter to assess response and adherence 6, 7, 8, 9, 10

For patients >75 years, moderate-intensity statin therapy is recommended after evaluating potential benefits, adverse effects, and drug interactions, and high-intensity statin therapy should be continued in those already tolerating it 5
Age alone is not a contraindication to statin therapy, but patients >75 years require careful evaluation of potential benefits versus adverse effects, particularly older thin or frail women 1, 4, 6, 7, 11
Asian patients should initiate statin therapy at lower doses due to increased risk of myopathy, and titrate carefully based on response and tolerability 7
Diabetic patients (age 40-75) should receive moderate-intensity statin therapy, with high-intensity statin therapy for those with multiple risk factors or aged 50-75 years 12, 13, 14, 15, 16

In addition to statin therapy, patients with ASCVD should receive lifestyle modifications, including a heart-healthy diet, regular physical activity, and weight management 4
The American College of Cardiology recommends reducing saturated fat intake to <7% of calories, limiting cholesterol intake to <200 mg/day, and reducing trans fatty acid intake 17
Increasing consumption of fresh fruits, vegetables, and low-fat dairy products, and regular physical activity (at least 150 minutes of moderate-intensity aerobic activity per week) are recommended to improve lipid profile and reduce cardiovascular risk 17, 18

Patient Category	Recommended Statin Therapy	Target LDL-C Reduction
High Risk (≥20% 10-year risk)	High-intensity statin	≥50%
Intermediate Risk (7.5% to <20% 10-year risk)	Moderate-intensity statin	≥30%
Borderline Risk (5% to <7.5% 10-year risk)	Moderate-intensity statin (if risk-enhancing factors present)	≥30%
Low Risk (<5% 10-year risk)	No statin therapy recommended	-
Diabetes (age 40-75 years)	At least moderate-intensity statin	≥30%
Diabetes with multiple ASCVD risk factors	High-intensity statin	≥50%
Established ASCVD (≤75 years)	High-intensity statin	≥50%
Established ASCVD (>75 years)	Moderate-intensity statin	≥50%